This content is current as of April 2022.

 

Dare to make a differene.

  • Movies
  • Graphics/Episodes

History belongs to the daring. To the determined visionaries who triumphed over conventional wisdom, taking humankind to the depths of the ocean, atop the highest peaks, into the skies,
and beyond. Yet mysteries remain unsolved.
There’s work to be done. People to help. And that’s our challenge.
On, April 1, 2022, Sumitomo Dainippon Pharma changed its name to Sumitomo Pharma. This moment is an opportunity to renew our commitment to innovative pharmaceuticals and healthcare solutions. We will continue to take on challenges and advance humankind in our three research focus areas of Psychiatry & Neurology, Oncology, and Regenerative Medicine & Cell Therapy, as well as in infectious diseases and other emerging health frontiers. Because good health starts with a name.

SCROLL

Progress2005Sumitomo Pharma’s challenges to date

  • 2005

    The Establishment of Sumitomo Dainippon Pharma

  • 2007

    First Step towards Global Expansion

    Commenced the in-house development of the atypical antipsychotic discovered in-house in the United States.

  • 2009

    Laying Down the Foundations for Global Business

    Acquired Sepracor Inc. (currently, Sunovion Pharmaceuticals Inc.) in order to build in-house development and marketing systems of the atypical antipsychotic developed in-house in the United States.

  • 2012

    Entry into Oncology Area

    Acquired Boston Biomedical, Inc. (currently, Sumitomo Pharma Oncology, Inc.), a US biotech company specializing in oncology area. Gained superb capability to discover and develop drugs in the area of oncology.

  • 2013

    Driving the Development in the Field of Regenerative Medicine/Cell Therapy

    Decision made to enter the field of Regenerative Medicine/Cell Therapy, by leveraging the experience, know-how, and network of contacts built through research in the field conducted over more than 20 years; established the Regenerative & Cellular Medicine Office as a dedicated business unit.

  • 2018

    A World First: Completion of “SMaRT,” a Manufacturing Plant for Regenerative Medicine & Cell Therapy

    “SMaRT,” a manufacturing plant for regenerative medicine & cell therapy —the world’s first facility dedicated to the commercial manufacture of regenerative medicine and cell therapy products derived from allogeneic iPS cells, which makes the manufacture of investigational agents as well as early-stage commercial production possible—was completed within the Central Research Laboratories.

  • 2019

    Mid-term Business Plan 2022 Drawn Up

    We believe that the pharmaceutical industry is facing a Time for Change when the establishment of non-conventional new business models is imperative to adapt to diversifying healthcare needs that include not only the creation of innovative new drugs but also making preventative medical care more widely available and contributing to global health. In April 2019, we formulated our Vision and the five-year Mid-term Business Plan 2022 (fiscal 2018 to fiscal 2022) based on this belief in order to solve social issues in the changing healthcare area.

  • 2019

    Accelerating Growth through Strategic Alliance with Roivant Sciences Ltd.

    Concluded the Agreement for Strategic Alliance with Roivant Sciences Ltd., thereby acquiring numerous pipeline assets, including those that have the potential to become blockbusters in the future, as well as DrugOME and Digital Innovation, the healthcare technology platforms which will accelerate our digital transformation (DX), and certain key employees. We accelerated our DX and pressed ahead with our “transformation into a data-driven pharmaceutical company” as well as “creation of new value and operational reform,” with a view to attaining sustained growth.

NowWhere Sumitomo Pharma currently stands

We aim to create innovative medicines by focusing our research efforts on Psychiatry & Neurology, Oncology, and Regenerative Medicine/Cell Therapy, where unmet medical needs are high.
We are also engaged in Infectious Disease with a view to contributing to global health.

In Japan, we are also focusing on Diabetes and engaged in business activities with the goal of becoming the number one company in this area.
In areas beyond pharmaceuticals , we aim to contribute to the realization of “Diversity in Wellbeing ” as a “Frontier Business” which transcends the boundaries of a conventional pharmaceutical company, by promoting the research, development, and commercialization of new healthcare solutions.

  • 01

    A New Treatment Option for Patients with
    Psychiatric or Neurological Disorders

    Research and development in the areas of Psychiatry and Neurology pose significant challenges. In addition to a track record of continuously innovating new therapeutic drugs for patients with schizophrenia and bipolar disorder primarily in North America and Japan, we also have a world-class development pipeline.

    Based on our proprietary drug discovery platform, built by incorporating cutting-edge technologies including Artificial Intelligence (AI) and patient-derived iPS cells, we are working on discovery of therapeutic agents for psychiatric disorders such as schizophrenia, depression, and development disorders, as well as neurological disorders such as dementia and Parkinson’s disease, all of which display low levels of treatment satisfaction.

  • 02

    Pursuing Research and Development of Cancer Drugs by Capitalizing on Our Competitive Advantage

    We are working on building our own proprietary pipeline by not just leveraging the technologies, drug seeds, and know-how we have acquired and accumulated through collaboration with the academia and biotech companies as well as our own research, but also strengthening our efforts in exploring new drug modalities.

    We aim to continuously create innovative products through our global research and development organizations based in Japan and the United States.

  • 03

    Leading the World in Regenerative Medicine/
    Cell Therapy

    Through open innovation with the academia and biotech companies, we are pursuing five research and development projects for regenerative medicine/cell therapy derived from iPS cells, with a view to providing therapies that can treat or cure diseases for which insufficient treatment options are available.

    We are steadily progressing our existing projects, whilst also conducting researches into next-generation regenerative medicine (gene therapy, organ regeneration, genome editing, and autologous cell therapy) as well as peripheral services such as diagnostics and rehabilitation.

  • 04

    Contributing to Global Health

    In collaboration with the academia and others, we are pursuing research and development projects for therapeutic agent for antimicrobial-resistant (AMR) bacterial infections, universal influenza vaccine, and malaria vaccines.

  • 05

    Becoming the Number One Domestic Pharmaceutical Company in Diabetes Area

    We hold an extensive line-up of products with different mechanisms of action which are indicated for Type 2 diabetes, and domestically we are ranked at the top level.

    We aim to become a true number one company which can offer a treatment which matches the conditions and lifestyles of patients.

  • 06

    Driving our Frontier Business

    Anticipating the advent of an era in which it will be difficult to achieve the required level of well-being through pharmaceuticals alone, we are pursuing the research, development, and commercialization of new healthcare solutions other than pharmaceuticals, which utilize digital technology among other things.

FutureThe future Sumitomo Pharma is aiming for

For Longer and Healthier Lives
We Unlock the Future with Cutting-Edge
Technology and Ideas

In pursuit of this vision, we aim to become a global leader in the three research focus areas of Psychiatry & Neurology, Oncology, and Regenerative Medicine/Cell Therapy, we are also engaged in research and development of pharmaceuticals for infectious diseases and vaccines, as well as our Frontier Business, which is expected to deliver synergy with our pharmaceuticals business, with a view to establishing a position as a “Global Specialized Player” by 2033.

  • About Sumitomo Pharma
  • The Sumitomo’s Business Philosophy / Corporate Philosophy
  • For Shareholders / Investors IR information

閉じる

Graphic

Challenge for the Sky

Flying has always been humankind’s ultimate dream.
In 1891, 12 years before the world’s first motor-operated aircraft, was invented and flown, a Japanese aviation pioneer discovered the principles of the airplane.
His name was Chuhachi Ninomiya. Undeterred by the lack of a suitable engine, Ninomiya used stethoscope tubing to drive the propellor—an idea perhaps inspired by his time as a pharmacist in the military—and his model aircraft flew for 10 meters. Later, Ninomiya became a director of a predecessor to Sumitomo Pharma. His desire to achieve lives on as part of Sumitomo Pharma today.

Graphic

Challenge for
Outer Space

The grand plan of sending humankind to the moon was once the dream of a single scientist. At a time when the Internet, cellphones, and even pocket calculators were science fiction, and driven by his desire to do something great, Wernher von Braun directed efforts to build a rocket and land it on the lunar surface. That leap was made more than 50 years ago at great cost for the benefit of all, and it paves the way for challenges to Mars and beyond for those brave enough to defy impossible.

Graphic

Challenge for
the Mountains

When asked why he wanted to scale the world’s highest peak, English mountaineer George Mallory famously replied: “Because it’s there.”
Many believe he spoke these words as an adventurer who longed to summit Everest, something no one had ever done before. Far beyond conventional wisdom, at an altitude above 8,000 m where thin air and fatigue can claim even those with oxygen masks, Mallory fell before reaching the summit. But his desire to do something great lived on, and 29 years later, in 1953, another was able to accomplish Mallory’s dream.
Some challenges are so great, they transcend generations.

Graphic

Challenge for
the Deep Sea

They say there’s a place on earth even harsher than outer space.
Far beneath the waves, at 10,000-meter depths great enough to swallow Mount Everest, the seabed is the world’s last unexplored frontier. An inhospitable blackness where no light penetrates the crushing pressure of 1,000 atmospheres. A place of extreme anxiety and fascination. Only 13 people* have ever reached the hadopelagic zone, fewer than the number who have ventured into space. No matter where our curiosity roams, the adventurous are ready explore it. What will we discover next?
* As of summer, 2020.

  • Sky
  • Space
  • Mountain
  • Deep Sea

Dare to make a differene.

History belongs to the daring. To the determined visionaries who triumphed over conventional wisdom, taking humankind to the depths of the ocean, atop the highest peaks, into the skies, and beyond.
Yet mysteries remain unsolved.
There’s work to be done. People to help. And that’s our challenge.
On, April 1, 2022, Sumitomo Dainippon Pharma changed its name to Sumitomo Pharma. This moment is an opportunity to renew our commitment to innovative pharmaceuticals and healthcare solutions. We will continue to take on challenges and advance humankind in our three research focus areas of Psychiatry & Neurology, Oncology, and Regenerative Medicine & Cell Therapy, as well as in infectious diseases and other emerging health frontiers. Because good health starts with a name.

  • Movies
  • Graphics/Episodes

Progress2005

Sumitomo Pharma’s challenges to date

  • 2005

    The Establishment of Sumitomo Dainippon Pharma

  • 2007

    First Step towards Global Expansion

    Commenced the in-house development of the atypical antipsychotic discovered in-house in the United States.

  • 2009

    Laying Down the Foundations for Global Business

    Acquired Sepracor Inc. (currently, Sunovion Pharmaceuticals Inc.) in order to build in-house development and marketing systems of the atypical antipsychotic developed in-house in the United States.

  • 2012

    Entry into Oncology Area

    Acquired Boston Biomedical, Inc. (currently, Sumitomo Pharma Oncology, Inc.), a US biotech company specializing in oncology area. Gained superb capability to discover and develop drugs in the area of oncology.

  • 2013

    Driving the Development in the Field of Regenerative Medicine/Cell Therapy

    Decision made to enter the field of Regenerative Medicine/Cell Therapy, by leveraging the experience, know-how, and network of contacts built through research in the field conducted over more than 20 years; established the Regenerative & Cellular Medicine Office as a dedicated business unit.

  • 2018

    A World First: Completion of “SMaRT,” a Manufacturing Plant for Regenerative Medicine & Cell Therapy

    “SMaRT,” a manufacturing plant for regenerative medicine & cell therapy —the world’s first facility dedicated to the commercial manufacture of regenerative medicine and cell therapy products derived from allogeneic iPS cells, which makes the manufacture of investigational agents as well as early-stage commercial production possible—was completed within the Central Research Laboratories.

  • 2019

    Mid-term Business Plan 2022 Drawn Up

    We believe that the pharmaceutical industry is facing a Time for Change when the establishment of non-conventional new business models is imperative to adapt to diversifying healthcare needs that include not only the creation of innovative new drugs but also making preventative medical care more widely available and contributing to global health. In April 2019, we formulated our Vision and the five-year Mid-term Business Plan 2022 (fiscal 2018 to fiscal 2022) based on this belief in order to solve social issues in the changing healthcare area.

  • 2019

    Accelerating Growth through Strategic Alliance with Roivant Sciences Ltd.

    Concluded the Agreement for Strategic Alliance with Roivant Sciences Ltd., thereby acquiring numerous pipeline assets, including those that have the potential to become blockbusters in the future, as well as DrugOME and Digital Innovation, the healthcare technology platforms which will accelerate our digital transformation (DX), and certain key employees. We accelerated our DX and pressed ahead with our “transformation into a data-driven pharmaceutical company” as well as “creation of new value and operational reform,” with a view to attaining sustained growth.

NowWhere Sumitomo Pharma currently stands

We aim to create innovative medicines by focusing our research efforts on Psychiatry & Neurology, Oncology, and Regenerative Medicine/Cell Therapy, where unmet medical needs are high. We are also engaged in Infectious Disease with a view to contributing to global health.

In Japan, we are also focusing on Diabetes and engaged in business activities with the goal of becoming the number one company in this area.
In areas beyond pharmaceuticals , we aim to contribute to the realization of “Diversity in Wellbeing ” as a “Frontier Business” which transcends the boundaries of a conventional pharmaceutical company, by promoting the research, development, and commercialization of new healthcare solutions.

  • 01

    A New Treatment Option for Patients with Psychiatric or Neurological Disorders

    Research and development in the areas of Psychiatry and Neurology pose significant challenges. In addition to a track record of continuously innovating new therapeutic drugs for patients with schizophrenia and bipolar disorder primarily in North America and Japan, we also have a world-class development pipeline.

    Based on our proprietary drug discovery platform, built by incorporating cutting-edge technologies including Artificial Intelligence (AI) and patient-derived iPS cells, we are working on discovery of therapeutic agents for psychiatric disorders such as schizophrenia, depression, and development disorders, as well as neurological disorders such as dementia and Parkinson’s disease, all of which display low levels of treatment satisfaction.

  • 02

    Pursuing Research and Development of Cancer Drugs by Capitalizing on Our Competitive Advantage

    We are working on building our own proprietary pipeline by not just leveraging the technologies, drug seeds, and know-how we have acquired and accumulated through collaboration with the academia and biotech companies as well as our own research, but also strengthening our efforts in exploring new drug modalities.

    We aim to continuously create innovative products through our global research and development organizations based in Japan and the United States.

  • 03

    Leading the World in Regenerative Medicine/Cell Therapy

    Through open innovation with the academia and biotech companies, we are pursuing five research and development projects for regenerative medicine/cell therapy derived from iPS cells, with a view to providing therapies that can treat or cure diseases for which insufficient treatment options are available.

    We are steadily progressing our existing projects, whilst also conducting researches into next-generation regenerative medicine (gene therapy, organ regeneration, genome editing, and autologous cell therapy) as well as peripheral services such as diagnostics and rehabilitation.

  • 04

    Contributing to Global Health

    In collaboration with the academia and others, we are pursuing research and development projects for therapeutic agent for antimicrobial-resistant (AMR) bacterial infections, universal influenza vaccine, and malaria vaccines.

  • 05

    Becoming the Number One Domestic Pharmaceutical Company in Diabetes Area

    We hold an extensive line-up of products with different mechanisms of action which are indicated for Type 2 diabetes, and domestically we are ranked at the top level.

    We aim to become a true number one company which can offer a treatment which matches the conditions and lifestyles of patients.

  • 06

    Driving our Frontier Business

    Anticipating the advent of an era in which it will be difficult to achieve the required level of well-being through pharmaceuticals alone, we are pursuing the research, development, and commercialization of new healthcare solutions other than pharmaceuticals, which utilize digital technology among other things.

FutureThe future Sumitomo Pharma is aiming for

For Longer and Healthier Lives
We Unlock the Future with Cutting-Edge
Technology and Ideas

In pursuit of this vision, we aim to become a global leader in the three research focus areas of Psychiatry & Neurology, Oncology, and Regenerative Medicine/Cell Therapy, we are also engaged in research and development of pharmaceuticals for infectious diseases and vaccines, as well as our Frontier Business, which is expected to deliver synergy with our pharmaceuticals business, with a view to establishing a position as a “Global Specialized Player” by 2033.

  • About Sumitomo Pharma
  • The Sumitomo’s Business Philosophy / Corporate Philosophy
  • For Shareholders / Investors IR information

Graphic

Close

Challenge for the Sky

Flying has always been humankind’s ultimate dream.
In 1891, 12 years before the world’s first motor-operated aircraft, was invented and flown, a Japanese aviation pioneer discovered the principles of the airplane.
His name was Chuhachi Ninomiya. Undeterred by the lack of a suitable engine, Ninomiya used stethoscope tubing to drive the propellor—an idea perhaps inspired by his time as a pharmacist in the military—and his model aircraft flew for 10 meters. Later, Ninomiya became a director of a predecessor to Sumitomo Pharma. His desire to achieve lives on as part of Sumitomo Pharma today.

Challenge for Outer Space

The grand plan of sending humankind to the moon was once the dream of a single scientist. At a time when the Internet, cellphones, and even pocket calculators were science fiction, and driven by his desire to do something great, Wernher von Braun directed efforts to build a rocket and land it on the lunar surface. That leap was made more than 50 years ago at great cost for the benefit of all, and it paves the way for challenges to Mars and beyond for those brave enough to defy impossible.

Challenge for the Mountains

When asked why he wanted to scale the world’s highest peak, English mountaineer George Mallory famously replied: “Because it’s there.”
Many believe he spoke these words as an adventurer who longed to summit Everest, something no one had ever done before. Far beyond conventional wisdom, at an altitude above 8,000 m where thin air and fatigue can claim even those with oxygen masks, Mallory fell before reaching the summit. But his desire to do something great lived on, and 29 years later, in 1953, another was able to accomplish Mallory’s dream.
Some challenges are so great, they transcend generations.

Challenge for the Deepest Sea

They say there’s a place on earth even harsher than outer space.
Far beneath the waves, at 10,000-meter depths great enough to swallow Mount Everest, the seabed is the world’s last unexplored frontier. An inhospitable blackness where no light penetrates the crushing pressure of 1,000 atmospheres. A place of extreme anxiety and fascination. Only 13 people* have ever reached the hadopelagic zone, fewer than the number who have ventured into space. No matter where our curiosity roams, the adventurous are ready explore it. What will we discover next?
* As of summer, 2020.

  • Sky
  • Space
  • Mountain
  • Deep Sea

閉じる